Occupational and Environmental Epidemiology & Net Teaching Unit, Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital of Munich (LMU), Munich, Germany.
Occupational and Environmental Epidemiology & Net Teaching Unit, Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital of Munich (LMU), Munich, Germany.
Ann Allergy Asthma Immunol. 2015 Jul;115(1):21-27.e2. doi: 10.1016/j.anai.2015.04.019. Epub 2015 May 23.
Accumulating evidence is indicating that hormonal factors play a role in new-onset allergic rhinitis and asthma after puberty.
To determine whether age at menarche and use of hormonal contraceptives predict new-onset allergic rhinitis and asthma after puberty in young German women.
A prospective community-based cohort study followed 1,191 girls 9 to 11 years old to early adulthood (19-24 years old). Self-administrated questionnaires concerning age at menarche, use of hormonal contraceptives, and status and age at onset of physician-diagnosed allergic rhinitis and asthma were collected at 16 to 18 and 19 to 24 years of age. Logistic regression models were used to analyze the incidence of asthma and allergic rhinitis after puberty and pooled estimates were obtained from the final model.
Eleven percent of girls developed allergic rhinitis after menarche and 3% reported new-onset asthma. Late menarche (>13 years of age) was statistically significantly inversely related to allergic rhinitis (adjusted odds ratio [OR] 0.32, 95% confidence interval [CI] 0.14-0.74) but did not reach the level of statistical significance for asthma (OR 0.32, 95% CI 0.07-1.42). Use of hormonal contraceptives was inversely associated with new-onset allergic rhinitis (OR 0.14, 95% CI 0.08-0.23) and asthma (OR 0.27, 95% CI 0.12-0.58) after puberty.
This study shows that girls with late onset of menarche are less likely to develop allergic rhinitis after puberty compared with those who have menarche at an average age. These findings also suggest that, in addition to endogenous hormones, hormonal contraceptives play a role and might protect young women from allergies and asthma.
越来越多的证据表明,激素因素在青春期后新发过敏性鼻炎和哮喘中起作用。
确定初潮年龄和激素避孕药的使用是否可预测德国年轻女性青春期后新发过敏性鼻炎和哮喘。
一项前瞻性基于社区的队列研究,对 1191 名 9 至 11 岁的女孩进行了随访,直至成年早期(19 至 24 岁)。在 16 至 18 岁和 19 至 24 岁时,通过自我管理的问卷收集了关于初潮年龄、激素避孕药使用情况以及医生诊断的过敏性鼻炎和哮喘的发病情况和发病年龄的信息。使用逻辑回归模型分析青春期后哮喘和过敏性鼻炎的发生率,并从最终模型中获得合并估计值。
11%的女孩在初潮后出现过敏性鼻炎,3%的女孩报告新诊断为哮喘。初潮晚(>13 岁)与过敏性鼻炎呈统计学显著负相关(调整后的优势比[OR]0.32,95%置信区间[CI]0.14-0.74),但与哮喘无统计学显著相关性(OR 0.32,95%CI 0.07-1.42)。青春期后,使用激素避孕药与新发过敏性鼻炎(OR 0.14,95%CI 0.08-0.23)和哮喘(OR 0.27,95%CI 0.12-0.58)呈负相关。
本研究表明,与初潮年龄正常的女孩相比,初潮较晚的女孩青春期后发生过敏性鼻炎的可能性较小。这些发现还表明,除了内源性激素外,激素避孕药也发挥作用,并可能保护年轻女性免受过敏和哮喘的影响。